Beginning as early as April 1, 2026, Medicare beneficiaries will pay no more than $50 per month for Lillys Zepbound (tirzepatide), available in a multi-dose pen, and for orforglipron, Lilly's once-daily obesity pill, provided both receive approval from the US Food and Drug Administration (FDA), according to a news release from Lilly
Step 3: Production of Eumelani, the dark, brown pigment associated with hyperpigmentation and tanning [4]
The sooner it starts, the greater the loss will be if left untreated
Rather than functioning as identical agents, the peptides appear to interact with separate receptor systems that may converge upon related physiological pathways, thereby creating an increasingly interesting subject for modern molecular investigations